Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Advaxis, Inc. (NASDAQ: ADXS).

Full DD Report for ADXS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADXS)

Midday Gainers / Losers (09/07/2018)
Gainers:  OKTA +20% . NVUS +17% . XENE +16% . NX +16% . DRNA +15% . ZEAL +15% . SHLO +15% . TIS +13% . FIVE +13% . MCFT +11% . More news on: Okta, Inc., Novus Therapeutics, Xenon Pharmaceuticals, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 07 2018 12:47
Advaxis Announces Pricing of Its Public Offering of Common Stock and Warrants
Advaxis, Inc.  (NASDAQ:ADXS) (“Advaxis” or the “Company”) announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock. Each share of common stock is ...
Source: Business Wire
Date: September, 07 2018 09:25
Premarket Losers as of 9:05 am (9/7/2018)
ADXS   -30%  on announcing public offering of common stock and warrants. More news on: Advaxis Inc., MER Telemanagement Solutions Ltd., Ascent Capital Group, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 07 2018 09:10
Advaxis, Inc. announces proposed underwritten public offering of common stock and warrants
Advaxis, Inc. ( ADXS -5.9% )  announced  that it intends to offer and sell in an underwritten public offering shares of its common stock. More news on: Advaxis Inc., Read more ...
Source: SeekingAlpha
Date: September, 06 2018 17:51
Advaxis, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants
Advaxis, Inc. (Nasdaq:ADXS) (“Advaxis” or the “Company”) announced today that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a warrant to p...
Source: Business Wire
Date: September, 06 2018 17:08
Biotech Analysis Central Pharma News: MannKind's Agreement, Advaxis' Partnership, Sanofi's FDA Approval
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. MannKind Establishes Partnership Deal For Potential Inhalation Product News: Recently, MannKind ( MNKD ) announced that it had established a collabo...
Source: SeekingAlpha
Date: September, 05 2018 06:16
Your Cancer Highlight: Advaxis Resurrects A 'Dead' Bone Cancer Program
One of the core criticisms that shareholders of Advaxis ( ADXS ) have had with management of the company has been an inability to capitalize on seemingly promising clinical data, as programs using their attenuated listeria-based immunotherapy languish on the vine, unable (apparently) to gain t...
Source: SeekingAlpha
Date: September, 04 2018 16:40
Advaxis licenses ADXS-HER2 to OS Therapies for evaluation in the treatment of osteosarcoma
Advaxis (NASDAQ: ADXS ) has granted a license to OS Therapies for the use of ADXS31-164, also known as ADXS-HER2, for evaluation in the treatment of osteosarcoma in humans. More news on: Advaxis Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: September, 04 2018 09:29
Advaxis Licenses ADXS-HER2 to OS Therapies for Evaluation in the Treatment of Osteosarcoma
Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, and OS Therapies LLC, a clinical-stage therapeutic company focused on the identification, development and commercialization of treatm...
Source: Business Wire
Date: September, 04 2018 08:00
Recent Analysis Shows Liberty TripAdvisor, Control4, Ferro, Advaxis, Frontier Communications, and Newpark Resources Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Liberty TripAdvisor Holdings, Inc. (NASDAQ:LTRPA), Control4 Corporation (...
Source: GlobeNewswire
Date: August, 28 2018 07:45

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-081.041.021.120.95019,928,487
2018-05-171.861.771.941.77694,162
2017-01-308.958.759.038.60385,424
2017-01-278.809.059.078.66463,796
2017-01-268.678.779.108.55710,512

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-11114,244265,08843.0966Short
2018-12-1083,033198,48641.8332Short
2018-12-0732,38179,21240.8789Short
2018-12-0633,368110,16730.2886Cover
2018-12-0419,54167,59928.9072Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADXS.


About Advaxis, Inc. (NASDAQ: ADXS)

Logo for Advaxis, Inc. (NASDAQ: ADXS)

Advaxis is a clinical stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio engineered to secrete an antigen/adjuvant fusion protein s that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS HPV is currently being evaluated in four clinical trials for human papillomavirus HPV associated cancers: recurrent/refractory cervical cancer India , locally advanced cervical cancer GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT , head amp neck cancer CRUK study, Clinical Trials.gov Identifier NCT , and anal cancer BrUOG study, Clinical Trials.gov Identifier NCT . Advaxis has over distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

 

Contact Information

 

 

Current Management

  • Thomas Moore / CEO
  • Daniel O Connor / EVP
  • Mark Rosenblum / Senior VP, CFO, Secretary
  • Robert Petit / Chief Scientific Officer
  • Thomas Moore / Chairman
  • Ronie A. Appel /
  • Richard Berman /
  • Thomas McKearn /
  • James Patton /
  • David Sidransky /

Current Share Structure

  • Market Cap: $98,350,036 - 05/14/2018
  • Authorized: 25,000,000 - 07/15/2013
  • Issue and Outstanding: 52,313,849 - 03/08/2018

 


Recent Filings from (NASDAQ: ADXS)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 12 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018

 

 


Daily Technical Chart for (NASDAQ: ADXS)

Daily Technical Chart for (NASDAQ: ADXS)


Stay tuned for daily updates and more on (NASDAQ: ADXS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ADXS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADXS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ADXS and does not buy, sell, or trade any shares of ADXS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/